Brief: Idorsia Seeks US Label Update For Quviviq
Tue 06:05
BRIEF-Idorsia Seeks US Label Update For Quviviq Oct 27 (Reuters) - IDORSIA LTD IDIA.S:
IDORSIA SEEKS US LABEL UPDATE FOR QUVIVIQ DAYTIME FUNCTIONING BENEFITS – FIRST PATIENTS ENROLLED IN DARI-DREAM
DARI-DREAM PHASE 3 STUDY TO RANDOMIZE 344 PARTICIPANTS TO QUVIVIQ 50 MG OR PLACEBO
DARI-DREAM PRIMARY ENDPOINT IS SUBJECTIVE TOTAL SLEEP TIME; SECONDARY ENDPOINTS INCLUDE IDSIQ SCORES
DARI-DREAM STUDY RESULTS EXPECTED DURING 2028
Source text: ID:nGNE4lwWMy
Further company coverage: IDIA.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))